OBJECTIVE: This study assessed the effects of planned duration of residential drug abuse treatment on recovery from drug use and on human immunodeficiency virus (HIV) risk behaviors. METHODS: Two concurrent randomized controlled trials of programs differing in planned duration were conducted: 6-month vs 12-month versions of a traditional therapeutic community program, and 3-month vs 6-month versions of a modified therapeutic community incorporating a relapse prevention and health education program. Outcomes, measured at least 16.5 months after admission, included time from admission to first drug use; severity of drug, alcohol, legal, and employment problems; and risky drug injection and sexual behaviors. RESULTS: Among 539 clients (86% of those enrolled), there were no significant effects of planned duration of treatment upon Addiction Severity Index scores or HIV risk behavior. In the relapse prevention program, clients randomized to the 6-month program had a longer time to first drug use than those in the 3-month program (hazard ratio = 0.74; 95% confidence interval = 0.58, 0.93). Employment problems at follow-up were significantly less severe among clients treated in the therapeutic community than among those in the relapse prevention program. CONCLUSIONS: No overall benefit of extending treatment beyond 6 months was found.
RCT Entities:
OBJECTIVE: This study assessed the effects of planned duration of residential drug abuse treatment on recovery from drug use and on human immunodeficiency virus (HIV) risk behaviors. METHODS: Two concurrent randomized controlled trials of programs differing in planned duration were conducted: 6-month vs 12-month versions of a traditional therapeutic community program, and 3-month vs 6-month versions of a modified therapeutic community incorporating a relapse prevention and health education program. Outcomes, measured at least 16.5 months after admission, included time from admission to first drug use; severity of drug, alcohol, legal, and employment problems; and risky drug injection and sexual behaviors. RESULTS: Among 539 clients (86% of those enrolled), there were no significant effects of planned duration of treatment upon Addiction Severity Index scores or HIV risk behavior. In the relapse prevention program, clients randomized to the 6-month program had a longer time to first drug use than those in the 3-month program (hazard ratio = 0.74; 95% confidence interval = 0.58, 0.93). Employment problems at follow-up were significantly less severe among clients treated in the therapeutic community than among those in the relapse prevention program. CONCLUSIONS: No overall benefit of extending treatment beyond 6 months was found.
Authors: J McCusker; M Vickers-Lahti; A Stoddard; R Hindin; C Bigelow; M Zorn; F Garfield; R Frost; C Love; B Lewis Journal: Am J Public Health Date: 1995-10 Impact factor: 9.308
Authors: F Vigna-Taglianti; F Mathis; R Diecidue; E Trogu; U Kirchmayer; J Ghibaudi; G Piras; A Camposeragna; A Saponaro; L Amato; M Davoli; F Faggiano; P P Pani Journal: Community Ment Health J Date: 2017-02-08
Authors: Wenhao Dai; Ryan Palmer; Aashna Sunderrajan; Marta Durantini; Flor Sánchez; Laura R Glasman; Fan Xuan Chen; Dolores Albarracín Journal: Psychol Addict Behav Date: 2020-04-20
Authors: Gabriela López; Lindsay M Orchowski; Madhavi K Reddy; Jessica Nargiso; Jennifer E Johnson Journal: Subst Abuse Treat Prev Policy Date: 2021-06-21
Authors: Wouter Vanderplasschen; Kathy Colpaert; Mieke Autrique; Richard Charles Rapp; Steve Pearce; Eric Broekaert; Stijn Vandevelde Journal: ScientificWorldJournal Date: 2013-01-15
Authors: Gabriel G Edwards; Cathy J Reback; William E Cunningham; Charles L Hilliard; Charles McWells; Sukrit Mukherjee; Robert E Weiss; Nina T Harawa Journal: JMIR Res Protoc Date: 2020-09-22